Drug Trial Radar · NCT01803282
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jun 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
236
Actual
Start
Mar 29, 2013
Primary completion
Apr 23, 2019
Study completion Apr 23, 2019
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Mar 4, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to determine the maximum tolerated dose of andecaliximab monotherapy and to evaluate the safety and tolerability of andecaliximab (formerly GS-5745) alone and in combination with chemotherapy. The study consists of 2 parts (Parts A and B). Participants can only qualify for and participate in 1 part. Part A is a sequential dose escalation to determine the maximum tolerated dose of andecaliximab in participants with advanced solid tumors that are refractory to or intolerant to standard therapy or for which no standard therapy exists. In Part A, participants will receive andecaliximab only. Part B is a dose expansion to obtain additional safety and tolerability data for andecaliximab in participants with advanced pancreatic adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, esophagogastric adenocarcinoma, colorectal cancer, or breast cancer. In Part B, participants will receive andecaliximab in combination with standard-of-care chemotherapy.
Conditions
- Pancreatic Cancer
- Non-small Cell Lung Cancer
- Esophagogastric Cancer
- Colorectal Cancer
- Breast Cancer
Interventions
AndecaliximabDrug
Administered intravenous infusion
GemcitabineDrug
Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
Nab-paclitaxelDrug
Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
CarboplatinDrug
Administered intravenously on Day 1 of each 21-day treatment cycle
PemetrexedDrug
Administered intravenously on Day 1 of each 21-day treatment cycle
LeucovorinDrug
Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
OxaliplatinDrug
Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
5-FUDrug
Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
BevacizumabDrug
Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
IrinotecanDrug
Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
PaclitaxelDrug
Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Treatment-Emergent Adverse EventsTime frame: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days
- Percentage of Participants Experiencing Laboratory AbnormalitiesTime frame: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Alabama Oncology
Birmingham, Alabama
Pinnacle Oncology Hematology
Scottsdale, Arizona
Comprehensive Blood and Cancer Center
Bakersfield, California
San Diego Pacific Oncology and Hematology Associates, Inc.
Encinitas, California
University of Southern California (USC)
Los Angeles, California
California Pacific Medical Center
San Francisco, California
UCLA Medical Center
Santa Monica, California
Florida Cancer Specialists
Sarasota, Florida
Parkview Research Center
Fort Wayne, Indiana
Indiana University Health Goshen Center for Cancer Care
Goshen, Indiana
Washington University School of Medicine
St Louis, Missouri
Cornell University
New York, New York
Greenville Health System, Institute for Translational Oncology Research
Greenville, South Carolina
Sarah Cannon Research Institute
Nashville, Tennessee
Vanderbilt
Nashville, Tennessee
UT Southwestern
Dallas, Texas
University of Utah
Salt Lake City, Utah
Northwest Medical Specialties
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.